作者：
SONG Hou-Pan;ZENG Mei-Yan;CHEN Xiao-Juan;CHEN Xin-Yi;YANG Yi-Jing;...
期刊：
数字中医药(英文),2019年2(3):136-146 ISSN：2096-479X
通讯作者：
Peng Jun
作者机构：
[CAI Xiong] Institute of Traditional Chinese Medicine Diagnostics, Hunan University of Chinese Medicine, Changsha, Hunan 410208, China;[ZENG Mei-Yan] College of Traditional Chinese Medicine, Hunan University of Chinese Medicine, Changsha, Hunan 410208, China;[YANG Yi-Jing; ZHOU Ya-Sha; TIAN Ye; LIU Xiao-Qing] Hunan Provincial Key Laboratory for Prevention and Treatment of Ophthalmology and Otolaryngology Diseases with Chinese Medicine, Changsha, Hunan 410208, China;[PENG Jun] Department of Ophthalmology, The First Affiliated Hospital of Hunan University of Chinese Medicine, Changsha, Hunan 410007, China;[SONG Hou-Pan; CHEN Xiao-Juan; CHEN Xin-Yi] Institute of Traditional Chinese Medicine Diagnostics, Hunan University of Chinese Medicine, Changsha, Hunan 410208, China<&wdkj&>College of Traditional Chinese Medicine, Hunan University of Chinese Medicine, Changsha, Hunan 410208, China
通讯机构：
[Peng Jun] D;Department of Ophthalmology, The First Affiliated Hospital of Hunan University of Chinese Medicine, Changsha, Hunan 410007, China
摘要：
目的观察中药密蒙花离子导入治疗干眼的疗效及可能作用机制。方法将60例(120眼)干眼患者随机分为观察组(30例60眼)和对照组(30例60眼) 。观察组予以中药密蒙花离子导入和玻璃酸钠滴眼液滴眼,对照组仅予以玻璃酸钠滴眼液滴眼,共治疗4周。于治疗前及治疗2、4周后比较两组患者干眼症状问卷评分、基础泪液分泌(Schirmer-Ⅰ) 、泪膜破裂时间(BUT) 、角膜染色评分和泪液白细胞介素6 (IL-6) 、细胞间黏附分子1 (ICAM-1)表达,治疗4周后评价临床疗效,随访3个月观察干眼复发情况。结果观察组临床疗效总有效率为93. 33%,对照组为80. 00%,观察组临床疗效优于对照组(P < 0. 01) 。治疗2、4周后,两组患者干眼症状问卷评分、Schirmer-Ⅰ、BUT、角膜染色评分和泪液IL-6、ICAM-1表达与本组治疗前比较均明显改善,且观察组均优于对照组(P < 0. 05或P < 0. 01) 。随访3个月,观察组复发率为14. 81%,低于对照组的39. 2%(P < 0. 05) 。结论中药密蒙花通过离子导入眼表组织,可消除或缓解干眼患者症状,降低复发率,抑制IL-6和ICAM-1炎症因子表达可能是其机制之一。 <&wdkj&>Objective To observe the effects of Chinese medicine Mimenghua (Flos Buddlejae) Iontophoresis on interleukin-6 (IL-6) ,intercellular adhesion molecule-1 (ICAM-1) in tear of dry eye patients and its possible mechanism. Methods A total of 60 patients (120 eyes) with dry eye were randomly divided into observation group (30 patients,60 eyes) and control group (30 patients,60 eyes) . The observation group was treated by Chinese medicine Flos Buddlejae iontophoresis and sodium hyaluronate eye drops,and the control group was only treated by sodium hyaluronate eye drops,for totally 4 weeks. The dry eye symptoms questionnaire scores,Schirmer-Ⅰtest,break-up time (BUT) ,cornea staining scores and the expression of IL-6,ICAM-1 in tear were compared before treatment and 2 and 4 weeks after treatment. The curative effects were evaluated after 4 weeks' treatment. The recurrence of dry eye was observed after 3 months of follow-up. Results The total effective rate was 93. 33% and 80. 00% in observation group in the control group. The clinical efficacy in the observation group was more significant (P < 0. 01) . After 2 weeks and 4 weeks treatment,dry eye symptoms questionnaire scores,Schirmer-Ⅰtest,BUT test,cornea staining scores and tear IL-6,ICAM-1 expression of two groups were significantly improved,and the observation group was better than the control group (P < 0. 05 or P < 0. 01) . After 3 months' follow-up,the recurrence rate of the observation group was 14. 81%,which was lower than 39. 2% in the control group (P < 0. 05) . Conclusion Chinese medicine Flos Buddlejae covered ocular surface by iontophoresis can eliminate or alleviate symptoms of dry eye patient, and reduce recurrence rate,the possible mechanisim might be inhibiting the expression of inflammatory cytokines IL-6 and ICAM-1.
摘要：
Objective To explore the possible mechanism of Yiqi Mingmu Pills (益气明目丸) in treatment of retinitis pigmentosa (RP) . Methods A total of 24 RCS rats were randomly divided into blank group,model group and Yiqi Mingmu Pills group,with 8 rats in each group. The blank group RCS rats (rdy +/+ ,p +/+) ,and the model group RCS rats (rdy -/,p -/-) were given 12 ml/(kg·d) of normal saline by gavage. The Yiqi Mingmu Pills group RCS rats (rdy -/,p -/-) were given 7. 8 g/(kg·d) of suspension turbid solution of Yiqi Mingmu Pills. After intragastric administration for 30 days,the structure of retina layers was observed by HE staining. Expressions of Fas and FasL in retinal tissues of each group were detected by immunohistochemistry and Western Blot method. Results HE staining showed that the retina thickness of rats in Yiqi Mingmu Pills group was significantly thicker than that of the model group. The retinal pigment epithelial band was partially visible,and part of the outer nuclear layer photoreceptor sensory ciliary layer was visible. The number of photoreceptor cell nuclei was higher than that of the model group. The outer layer,outer core layer,and the visual cone layer were clearer and thicker than the model group. The results of immunohistochemistry showed that the expression of Fas and FasL protein in the model group was significantly higher than that in the blank group (P < 0. 01) . Compared with the model group,the expression of Fas and FasL protein in Yiqi Mingmu Pill group decreased significantly (P < 0. 05 or P < 0. 01) ,and there was no significant difference with the blank group (P > 0. 05) . Western blot analysis showed that the expression of Fas and FasL protein in the model group was significantly higher than that in the blank group (P < 0. 01) . Compared with the model group,the expression of Fas protein in Yiqi Mingmu Pill group was not statistically significant (P > 0. 05) ,and the expression of FasL protein was significantly lower,but was still higher than that of the blank group (P < 0. 01) . Conclusion Yiqi Mingmu Pills has protective effects on the ultrastructure of RP retina. Yiqi Mingmu Pills can reduce the apoptosis of retinal photoreceptor cells and protect the visual cells by inhibiting the expression of Fas and FasL on the retina.
作者机构：
[Xiang L.; Peng-Fei J.] Hunan University of Chinese Medicine, Changsha, Hunan 410208, China;Department of Ophthalmoloty, the First Affiliated Hospital of Hunan University of Traditional Chinese Medicine, Changsha, Hunan 410007, China;[Qing-Hua P.] Hunan University of Chinese Medicine, Changsha, Hunan 410208, China, Department of Ophthalmoloty, the First Affiliated Hospital of Hunan University of Traditional Chinese Medicine, Changsha, Hunan 410007, China
通讯机构：
[Qing-Hua, P.] H;Hunan University of Chinese Medicine, Changsha, Hunan, China
